Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
FAK-IN-14
Cat. No.:
0225LY-0585
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
FAK-IN-14 is a focal adhesion kinase (FAK) inhibitor that triggers cell cycle arrest and apoptosis; while it weakly affects Akt and mTOR, it shows significant inhibition of FAK, Pyk2, and FGFR1.
Synonym:
2766666-22-0
CAS No.:
2766666-22-0
Compound CID:
169450787
Formula:
C21H24BrN7OS
Formula Weight:
502.43
Specification
Targets&IC50:
FAK: 0.2438 nM
Relative Density:
1.489 g/cm3 at 20°C.
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
FAK-IN-14 can be used in cell migration and adhesion studies to investigate the selective inhibition of focal adhesion kinase.
Library Information
Target:
MEK; Akt; c-Kit; mTOR; PYK2; FAK; FGFR
Receptor:
FAK; PYK2; FGFR1; mTOR; MEK1/2; c-Kit; Akt
Pathways:
Cytoskeletal signaling; PI3K/Akt/mTOR signaling; Tyrosine kinase/adaptors; MAPK; Angiogenesis
Plate Number:
AOCL-8
Plate Location:
e10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
20 mg/mL; 39.81 mM
